The third quarter featured 21 device M&A transactions, 10 of which had disclosed values that together totaled $7.1bn, versus the second quarter, when 14 deals totaled $2bn. Three transactions cracked the billion dollar mark compared to only one deal meeting this milestone in the second quarter.
Dealmaking Quarterly Statistics, Q3 2021
A look at M&A and alliance activity across the biopharma, medical device and in vitro diagnostics industries, July-September 2021
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
